Valuation : Endonovo Therapeutics Inc

Market Cap 2.77M 2.39M 2.25M 2.05M 3.84M 262M 3.85M 26.53M 10.29M 134M 10.41M 10.19M 433M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.54M 8.04M 7.34M 13.73M 937M 13.77M 94.96M 36.85M 481M 37.27M 36.46M 1.55B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 29/02/2012
Investor Relations Contact - 30/04/2014
Corporate Officer/Principal 70 28/02/2022
Director TitleAgeSince
Chairman 61 29/02/2012
Change 5-day change 1-year change 3-year change Capi.($)
-1.79%-3.82%+38.74%+91.90% 69.02B
-2.06%-0.18%+41.53%+88.17% 66.32B
-0.39%+6.51%-11.42%+378.78% 27.66B
+1.24%+2.01%+0.61%-14.65% 25.84B
-3.00%-2.61%+34.45%+11.39% 26.54B
-1.46%+0.42%+24.07%-18.70% 20.4B
-2.96%-16.03%+213.13%+375.00% 17.63B
-1.49%-6.69%-4.69%+539.74% 15.15B
-0.37%+8.37%+57.87%+164.98% 14.65B
Average -1.35%-0.66%+43.81%+179.62% 31.47B
Weighted average by Cap. -1.50%-0.45%+39.08%+139.17%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.05 0.1 6.9 0.1 0.7 0.27 3.54 0.27 0.27 11.41 0.14 0.12 0.11 0.1 0.19 12.78 0.19 1.29 0.5 6.56 0.51 0.5 21.12
Net income -3.1M -2.67M -2.51M -2.3M -4.3M -293M -4.31M -29.7M -11.53M -150M -11.66M -11.4M -485M -18.47M -15.9M -14.96M -13.66M -25.56M -1.74B -25.63M -177M -68.59M -895M -69.37M -67.86M -2.88B
Net Debt 7.1M 6.11M 5.74M 5.25M 9.82M 670M 9.84M 67.88M 26.34M 344M 26.64M 26.06M 1.11B 7.15M 6.16M 5.79M 5.29M 9.9M 675M 9.92M 68.43M 26.56M 347M 26.86M 26.27M 1.12B
Logo Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-